Clinical Trials Matching Service
Clinical trials are the primary means by which new cancer treatments are developed, tested, and approved for use. Most stomach (gastric) cancer patients are diagnosed at advanced stages, so treatment is difficult and complex. Therefore, clinical trials for new drugs are essential. Currently, numerous trials are underway in cancer centers across the country and the world, directed at improving the treatment and outcomes for stomach, esophageal, and GE junction cancer patients at all stages. Every patient diagnosed with these diseases should ask about clinical trials and should be treated in a facility which participates in research studies. While not every patient will end up enrolling in a trial, it is critical to be aware of the importance of these studies in advancing the treatment for stomach, esophageal, and GE junction cancer and to have access to an appropriate trial if needed.
At Debbie’s Dream Foundation: Curing Stomach Cancer (DDF), we recognize the crucial importance of diversity in clinical trials. Ensuring that clinical trial participants reflect the diverse populations who will use these treatments is essential for developing effective and safe medical advancements. In partnership with Arcus Biosciences, we proudly present an informative interview featuring Dr. Albert Lockhart, Director of Hematology & Oncology at MUSC and DDF Scientific Medical Advisory Board member. This interview highlights the disparities in clinical trial representation and underscores our commitment to health equity. Watch the full video clip and join us in advocating for inclusive research that benefits everyone.
Cancer Clinical Trials Educational Videos
Co-branded with CancerCare and featuring other industry partners, these videos provide invaluable insights, resources, and support to help you navigate a cancer clinical trial journey with confidence and understanding.
EDGE-Gastric is a Phase 2 clinical trial studying a combination of treatments including domvanalimab (an anti-TIGIT antibody) and/or zimberelimab (an anti-PD-1 antibody), plus chemotherapy, for people with an upper gastrointestinal tract (GI) cancer that cannot be removed with surgery (unresectable) that has spread to other parts of the body (metastasized). For more information on the investigational study, click the button below.
Massive Bio connects patients to the best treatments and clinical trials available. Our team and AI technology work together to identify clinical trials that meet your needs. In addition to identifying eligible trials, our clinical team and experts will answer your questions and provide support during the enrollment process. Massive Bio is dedicated to ensuring all patients have access to clinical trials, regardless of where they live. Learn more and find eligible trials today by completing this short online form.
Matching Service & Information for Stomach/Gastric, Esophageal, and GE Junction Cancer
Debbie's Dream Foundation: Curing Stomach Cancer has partnered with EmergingMed to provide free clinical trial matching services to stomach, esophageal, and GE junction cancer patients, family members, and caregivers. For more information on clinical trials and to find clinical trials, simply click the button below.
